# When Pain Outlasts Our Drugs: The Case for Sustained-Release Analgesia in Sheep

## TL;DR

This paper discusses how sustained-release meloxicam could provide longer pain relief for sheep during routine procedures, improving animal welfare and farm efficiency.

## Contribution

The paper highlights the development and potential of sustained-release meloxicam formulations for prolonged analgesia in sheep.

## Key findings

- Current pain relief in sheep lasts only 24–36 hours, while pain can persist for days or weeks.
- Sustained-release meloxicam formulations show promise for longer analgesia with a single dose.
- Challenges remain in achieving consistent drug delivery and optimal concentrations.

## Abstract

Routine husbandry procedures in sheep can cause pain that lasts for several days or longer, but current pain relief options usually provide only short-term relief. Because sheep are rarely re-handled after routine procedures, pain relief strategies that require repeated dosing are poorly aligned with commercial sheep production systems. Sustained-release formulations of the pain-relieving drug meloxicam are being developed to deliver longer-lasting analgesia from a single treatment, reducing the need for repeated handling of animals. Recent studies suggest these formulations have the potential to improve animal welfare and on-farm efficiency, although further work is needed to ensure consistent and reliable pain relief. Overall, sustained-release meloxicam represents a promising approach to improving pain management during routine sheep husbandry procedures.

Pain associated with routine husbandry procedures in sheep can persist for several days or even weeks, yet current analgesic options, such as the non-steroidal anti-inflammatory drug (NSAID) meloxicam, typically provide only 24–36 h of analgesia. This mismatch between pain duration and analgesic coverage represents a fundamental limitation of current pain-management strategies in sheep. Sustained-release (SR) formulations are emerging as a promising approach to deliver longer-lasting pain relief from a single dose, reducing the need for repeated handling, and improving both animal welfare and farm efficiency. Emerging evidence highlights both the promise and limitations of different strategies to extend therapeutic coverage beyond 72 h. While preliminary results are encouraging, challenges remain in achieving consistent pharmacokinetic profiles and optimal peak concentrations. Advancing SR meloxicam formulations could support widespread uptake of welfare-focused innovations in the sheep industry. Although not yet widely available, sustained-release meloxicam represent a promising step towards making routine husbandry procedures more humane and efficient.